Some malignancies associated with the(2;5) and overexpression of ALK protein in anaplastic large T/null cell lymphoma.
A member of the tumor necrosis receptor (TNFR) superfamily.
A transmembrane glycoprotein receptor with an extracellular domain, a transmembrane domain and an intracellular domain.
Expression is increased and proliferative or malignant lymphocytes.
CD30 expression leads to activation of the NFkB pathway.
Highly expressed in some malignant cells, but has almost no expression and many normal cells.
In healthy tissue, the majority of CD30 expression is limited to activated B cells, T cells, and natural killer cells, although activated lymphocytes make up those than 1% of the circulating cells in the blood.
CD30 is universally expressed in classical Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma, as well as primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
Can be used for diagnosis and as a target for treatment.
Known previously as Ki-1 antigen.
The best modality to assess for CD30 expression is formalin fixed paraffin embedded tumor tissue.
It is routinely detected by immunohistochemical staining.
CD30 expression can be measured by flow cytometry on peripheral blood, bone marrow, and body fluids and there are enzyme-linked immunoabsorbent assays for measuring soluble CD3O expression.
Immunohistochemistry has the advantage of antigenic expression with tumor cell morphologic features that facilitate diagnosis and classification of malignant tissue.
A lymphoid activating molecule that is a transmembrane protein with characteristics of the tumor necrosis factor receptor family.
CD 30 protein similar to the nerve growth factor superfamily and signaling through this molecule may promote tumor growth.
Encoded by gene 1p36, a frequent location for ab2242ations and lymphoma and opportunistic site for viral incorporation.
The binding of CD30 ligand to CD30 induces trimerization and recruits molecules resulting in signal pathway activation.
CD30 receptors can activate mitogen activated protein kinase pathway or inhibit kBkinase/nuclear factor kB pathway.
Highly soluble CD30 levels correlate with tumor burden, poor prognosis, disease activity and has prognostic significance in Hodgkin’s lymphoma and ALCL.
CD30 expressed on Hodgkin lymphoma cells but not on most non-cancer cells.
CD30 mediates survival of malignant Reed-Sternberg cells.
CD30 drives crosstalk with tumor environment.
Soluble CD30 has been identified in rheumatoid arthritis, SLE, systemic sclerosis, atopic dermatitis, Graves’ disease, Hashimoto’s thyroiditis, Wegener’s granulomatosis and Omenn syndrome.
CD30-positive cutaneous T-cell lymphoproliferative disorders include lymphomatoid papulosis and anaplastic large cell lymphoma.
Such cells are larger than normal lymphocytes, have basophilic cytoplasm, large nuclei with prominent nucleolus and resemble immunoblasts.
CD30-positive cells are often bi-nucleated, oral multinucleated and are similar to Reed- Sternberg cells.
Expressed on the surface of Reed-Sternberg cells, anaplastic large cell lymphomas, embryonal carcinomas, some subtypes of B cell non-Hodgkin’s lymphomas and mature T-cell lymphomas.
Recently reported in AML, diffuse B cell lymphoma , and adult T-cell leukemia/lymphoma.
Normal expression of CD30 is restricted to a small population of activated B cells and T cells and a small percentage of eosinophils.
Treatment of the CD 30 positive lymphomas with anthracycline containing regimens results in response rates of 76-88%, but complete remission rates only 39-53%.
The number of patients with CD30 positive lymphoma that remain progression free or disease free after five years is relatively low.
Normal tissues rarely express CD30
Brentuximab is an anti-CD30 agent.